Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluciclovine PET in Prostate Cancer with Biochemical Recurrence and Negative PSMA PET
NCT05722925Phase 4Active, not recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fluciclovine f 18 in prostate cancer (PCa), sponsored by OHSU Knight Cancer Institute. Started Oct 2023; status: active, not recruiting.
02
Drugs
fluciclovine f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05722925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722925.